Search Results

The most recent developments from Octapharma’s Haematology portfolio will be presented at the 32nd Congress of the International Society on Thrombosis and Haemostasis on June 22–26, 2024, in Bangkok, Thailand.

Octapharma USA , Inc. announced the U.S. Food and Drug Administration (FDA) has granted orphan drug exclusivity for wilate®, von Willebrand Factor/Coagulation Factor VIII Complex (Human) Lyophilized Powder for Solution for Intravenous Injection, for routine prophylaxis to reduce the frequency of bleeding episodes in adults and children 6 years of age and older with von Willebrand disease (VWD).

Octapharma USA, Inc. has appointed pharmaceutical industry veteran Kelly Hearn as Vice President of Commercial Development & Marketing, assuming immediate leadership of the product marketing team as the company continues to grow its presence in the U.S. market.

The CDC’s Advisory Committee on Immunization Practices on Wednesday backed the use of Merck’s Capvaxive and Pfizer’s Prevnar 20 in adults between 50-64 years of age, opening a bigger market for the respective companies.

MorphoSys AG announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG.

Octapharma USA has announced Balfaxar® is now available. The new non-activated four factor prothrombin complex concentrate, approved by the U.S. FDA this summer, is indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy in adult patients with need for urgent surgery or invasive procedures.

Octapharma USA announced the expansion of the U.S. Food and Drug Administration (FDA) approval for wilate ® , von Willebrand Factor/Coagulation Factor VIII Complex (Human) Lyophilized Powder for Solution for Intravenous Injection.